GC
TEVA icon

Grace Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Grace Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$32K – 237
2018
Q3 		$32K Hold
1,500
– – 0.01% 200
2018
Q2 		$36K Buy
+1,500
New +$30.6K 0.01% 210
2017
Q3 		– Sell
-56,865
Closed -$1.89M – 97
2017
Q2 		$1.89M Sell
56,865
-17,290
-23% -$535K 0.76% 54
2017
Q1 		$2.38M Buy
74,155
+1,160
+2% +$39.6K 0.98% 48
2016
Q4 		$2.65M Buy
+72,995
New +$2.91M 1.2% 43

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Grace Capital's TEVA Position: Q4 2018 in Review

Grace Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 1,500 shares — an estimated $32K sold.

Grace Capital first reported a position in TEVA in Q4 2016 and held it in 5 quarters. The position peaked at $2.65M in Q4 2016. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Grace Capital reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Grace Capital sold 1,500 Teva Pharmaceuticals shares in Q4 2018, an estimated $32K.
  • Grace Capital first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Grace Capital's Teva Pharmaceuticals position peaked at $2.65M in Q4 2016.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Grace Capital's 13F filing for Q4 2018, filed 15 Feb 2019.